IP Library Granted Patent US 7,220,418
Granted Patent B1
US 7,220,418 · App. 10/030,390 · Granted May 22, 2007

Delivery of trefoil peptides

Assignee: Vlaams Interuniversitair Instituut voor Biotechnologie
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,220,418
App. No.
10/030,390
Granted
May 22, 2007
Kind
B1
Abstract

The present invention relates to a microorganism, preferably a bacterial strain, preferably a non-pathogenic strain, preferably a non-invasive strain, preferably a food grade strain, preferably a gram-positive bacterial strain, delivering a trefoil peptide in vivo. Preferably said trefoil peptide is TFF1. The present invention further relates to a method for the delivery of trefoil peptide to the gastro-intestinal tract comprising the administration of such a bacterial strain. The present invention also relates to a pharmaceutical composition comprising a trefoil peptide delivering bacterium as well as methods of treatment of acute gastro-intestinal inflammatory diseases comprising administration of said transformed bacterial strains, particularly for treating acute colitis, including but not limited to acute flare-ups of Crohn's disease and ulcerative colitis in humans, as well as for treating gastro-intestinal disorders of a similar nature in other animal species.

Claims (12)

1. A method of treatment of a colon disorder in an individual comprising oral administration of a therapeutically effective amount of a recombinant food grade gram-positive bacterium expressing a trefoil peptide in the colon of said individual.

2. The method of claim 1 , wherein the colon disorder involves lesions.

3. The method of claim 1 , wherein the recombinant food grade gram-positive bacterium is a lactic acid fermenting bacterium.

4. The method of claim 3 , wherein the lactic acid fermenting bacterium is Lactococcus or Lactobacillus.

5. The method of claim 4 , wherein the Lactococcus is Lactococcus lactis.

6. The method of claim 1 , wherein the trefoil peptide is are TFF1 peptide.

7. The method of claim 1 , wherein the colon disorder is Crohn's disease (enteritis regionalis), ulcerative colitis (colitis ulcerosa) or acute colitis.

8. The method of claim 1 , wherein the oral administration is by a gastric catheter.

9. The method of claim 1 , wherein the recombinant food grade gram-positive bacterium comprises a recombinant vector comprising coding sequence of said trefoil peptide under the control of a suitable promoter sequence and a suitable secretion signal sequence.

10. The method of claim 1 , wherein the recombinant food grade gram-positive bacterium comprises the nucleotide sequence of SEQ ID NO. 1, SEQ ID NO. 2, or SEQ ID NO. 3.

11. The method of claim 1 , wherein the therapeutically effective amount of said recombinant food grade gram-positive bacterium is at least 10 8 cells of said bacterium.

12. The method of claim 1 , wherein the individual is a human or an animal.

Assignments (3)
CHANGE OF NAME Recorded Jan 28, 2016
From: ACTOGENIX NV
To: INTREXON ACTOBIOTICS NV
Reel/Frame 037627/0463 →
DEED OF ASSIGNMENT Recorded Feb 23, 2007
From: VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE
To: ACTOGENIX N.V.
Reel/Frame 018952/0630 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 16, 2002
From: HANS, WOLFGANG CHRISTIAN; REMAUT, ERIK RENE; STEIDLER, LOTHAR; UNIVERSITEIT GENT
To: VLAAMS INTERUNIVERSITAIR INSTITUT VOOR BIOTTECHNOLOGIE
Reel/Frame 012988/0376 →
Priority Claims (1)
EP 99870143 · Jul 5, 1999 · regional